219 related articles for article (PubMed ID: 8285625)
1. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.
Supparatpinyo K; Nelson KE; Merz WG; Breslin BJ; Cooper CR; Kamwan C; Sirisanthana T
Antimicrob Agents Chemother; 1993 Nov; 37(11):2407-11. PubMed ID: 8285625
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine.
Boon-Long J; Mekha N; Poonwan N; Kusum M; Mikami Y; Yazawa K; Konyama K
Mycoses; 1996; 39(11-12):453-6. PubMed ID: 9145003
[TBL] [Abstract][Full Text] [Related]
3. Disseminated Penicillium marneffei infection in southeast Asia.
Supparatpinyo K; Khamwan C; Baosoung V; Nelson KE; Sirisanthana T
Lancet; 1994 Jul; 344(8915):110-3. PubMed ID: 7912350
[TBL] [Abstract][Full Text] [Related]
4. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children.
Sirisanthana V; Sirisanthana T
Pediatr Infect Dis J; 1995 Nov; 14(11):935-40. PubMed ID: 8584358
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in Cambodia.
Sar B; Boy S; Keo C; Ngeth CC; Prak N; Vann M; Monchy D; Sarthou JL
J Clin Microbiol; 2006 Nov; 44(11):4208-10. PubMed ID: 16971649
[TBL] [Abstract][Full Text] [Related]
6. In vitro sensitivity of Penicillium marneffei and Pythium insidiosum to various antifungal agents.
Sekhon AS; Padhye AA; Garg AK
Eur J Epidemiol; 1992 May; 8(3):427-32. PubMed ID: 1397206
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients.
Sirisanthana T; Supparatpinyo K; Perriens J; Nelson KE
Clin Infect Dis; 1998 May; 26(5):1107-10. PubMed ID: 9597237
[TBL] [Abstract][Full Text] [Related]
8. Penicillium marneffei: types and drug susceptibility.
Imwidthaya P; Thipsuvan K; Chaiprasert A; Danchaivijitra S; Sutthent R; Jearanaisilavong J
Mycopathologia; 2001; 149(3):109-15. PubMed ID: 11307592
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
Van Cutsem J
Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal drug susceptibilities of Penicillium marneffei from China.
Liu D; Liang L; Chen J
J Infect Chemother; 2013 Aug; 19(4):776-8. PubMed ID: 23104584
[TBL] [Abstract][Full Text] [Related]
13. Penicillium marneffei infection in patients infected with human immunodeficiency virus.
Supparatpinyo K; Chiewchanvit S; Hirunsri P; Uthammachai C; Nelson KE; Sirisanthana T
Clin Infect Dis; 1992 Apr; 14(4):871-4. PubMed ID: 1315586
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the treatment of systemic fungal infections.
Walsh TJ
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
[TBL] [Abstract][Full Text] [Related]
15. [Choice and monitoring of the treatment of systemic mycoses. Value and limitations of in vitro tests].
Eloy O; Joly V; Ghnassia JC; Carbon C; Yeni P
Presse Med; 1992 May; 21(20):937-42. PubMed ID: 1322537
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
17. Infection due to Penicillium marneffei.
Sirisanthana T
Ann Acad Med Singap; 1997 Sep; 26(5):701-4. PubMed ID: 9494682
[TBL] [Abstract][Full Text] [Related]
18. Penicillium marneffei infection in a Swedish HIV-infected immunodeficient narcotic addict.
Julander I; Petrini B
Scand J Infect Dis; 1997; 29(3):320-2. PubMed ID: 9255902
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole.
Sekhon AS; Garg AK; Padhye AA; Hamir Z
Eur J Epidemiol; 1993 Sep; 9(5):553-8. PubMed ID: 8307142
[TBL] [Abstract][Full Text] [Related]
20. In-vitro evaluation of antifungal agents in the treatment of yeast peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).
Edwards R; Birrell LN; Finch RG
Chemioterapia; 1987 Feb; 6(1):3-7. PubMed ID: 3829134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
